Loading…
Loading…
Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.
C4 Therapeutics, Inc. (CCCC) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.37 per share a year ago.
Here is how C4 Therapeutics, Inc. (CCCC) and Illumina (ILMN) have performed compared to their sector so far this year.
Does C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.
C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide Transcript
Here is how C4 Therapeutics, Inc. (CCCC) and Clene Inc. (CLNN) have performed compared to their sector so far this year.
At the 100 µg Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate, Including Complete Responses and Minimal Residual Disease (MRD) Negative Status
I initiate C4 Therapeutics (CCCC) with a "Buy rating," driven by robust progress of its next-gen CELMoD cemsidomide in relapsed/refractory multiple myeloma. Company's lead program advances through phase 2 MOMENTUM and phase 1b combination studies, with key data catalysts expected at EHA 2026 and throughout 2026–2027. Strong financial position with $268.3M cash as of March 2026 supports operations into 2028, enabling continued pipeline expansion and clinical execution.